Skip to Content

NexHA (Canada)

This page contains information on NexHA for veterinary use.
The information provided typically includes the following:
  • NexHA Indications
  • Warnings and cautions for NexHA
  • Direction and dosage information for NexHA

NexHA

This treatment applies to the following species:
Manufacturer: Vétoquinol

DIN 02375176

[HYALURONATE SODIUM INJECTION]

STERILE

VETERINARY USE ONLY

For Intravenous or Intra-Articular Use in Horses Only

Description

NexHA® (hyaluronate sodium injection) is a clear, colourless solution of low viscosity. It is administered by intravenous or intra-articular injection.

NexHA® is extracted from the capsule of Streptococcus spp. and purified, resulting in a pure form of hyaluronate sodium which is essentially free of protein and nucleic acids. The solution is pyrogen free, sterile, and does not contain a preservative.

Each mL contains 10 mg hyaluronate sodium (active ingredient), 8.5 mg sodium chloride, 0.223 mg sodium phosphate dibasic and 0.04 mg sodium phosphate monobasic. The pH is adjusted to between 6.5 and 8.0 with sodium hydroxide or hydrochloric acid.

THERAPEUTIC CLASSIFICATION: Anti-inflammatory.

NexHA Indications

NexHA® is indicated in the treatment of joint dysfunction of the carpus or fetlock in horses due to non-infectious synovitis associated with equine osteoarthritis.

Dosage and Administration

Intravenous-4 mL (40 mg). Intra-articular-2 mL (20 mg) in the carpus or fetlock. Treatment may be repeated at weekly intervals for a total of three treatments.

Strict aseptic technique should be observed when administering by intra-articular injection. As with any intra-articular procedure, proper injection site disinfection and animal restraint are important. Excess joint fluid should be aseptically removed prior to injection. Care should be taken to avoid scratching the cartilage surface with the tip of the injection needle. Diffuse swelling lasting 24 to 48 hours may result from movement of the needle while in the joint space.

Horse should be given stall rest after treatment before gradually resuming normal activity.

Discard any unused portion of this drug and the empty vial after opening.

Contraindications

There are no known contraindications for the use of an injectable solution of hyaluronate sodium in horses.

CAUTIONS: Radiographic evaluation should be carried out in cases of acute lameness to ensure that the joint is free from serious fractures. As with any intra-articular treatment, special precautions must be followed as to injection technique and sterility for prevention of possible swelling or infection. Intra-articular injections should not be made through skin that has been recently fired or blistered, or that has excessive scurf and counterirritant on it.

Safety in breeding animals has not been determined with an injectable solution of hyaluronate sodium.

Warnings

Not to be administered to horses that are to be slaughtered for use in food. Keep out of reach of children.

Adverse Reactions

No local or systemic effects were observed in the clinical field trials with either intravenous or intra-articular injections.

Clinical Pharmacology

Glycosaminoglycan, commonly referred to as hyaluronic acid, can exist in the following forms depending upon the chemical environment in which it is found: as the acid, hyaluronic acid; as the sodium salt, sodium hyaluronate (hyaluronate sodium); or as the hyaluronate anion. These terms may be used interchangeably but in all cases, reference is made to the glycosaminoglycan composed of repeating subunits of D-glucuronic acid and N-acetyl-D-glucosamine linked together by glycosidic bonds. Since this product originates from a microbial source, there is no potential for contamination with dermatan or chondroitin sulfate or any other glycosaminoglycan.

Hyaluronic acid is a naturally occurring substance present in connective tissue, skin, vitreous humour and the umbilical cord in all mammals. High concentration of hyaluronic acid is also found in the synovial fluid. It also constitutes the major component of the capsule of certain microorganisms. The hyaluronic acid produced by bacteria is of the same structure and configuration as that found in mammals.

The actual mechanism of action for hyaluronate sodium in the healing of degenerative joint disease is not completely understood. One major function appears to be the regulation of normal cellular constituents. This effect decreases the impact of exudation, enzyme release and subsequent degradation of joint integrity. Additionally, hyaluronate sodium exerts an anti-inflammatory action by inhibiting the movement of granulocytes and macrophages.1

Hyaluronate molecules are long chains which form a filter network interspersed with normal cellular fluids. It is widely accepted that injection directly into the joint pouch enhances the healing of inflamed synovium by restoring lubrication of the joint fluid. This further supplements the visco-elastic properties of normal joint fluid.

SAFETY INFORMATION: An injectable solution of hyaluronate sodium was administered to normal horses at one, three and five times the recommended intra-articular dosage of 20 mg and the intravenous dosage of 40 mg. Treatments were given once weekly for nine consecutive weeks (three times the maximum duration). No systemic clinical signs were observed nor were there any adverse effects upon hematology or clinical chemistry parameters. A transient, slight to mild post-injection swelling of the joint capsule occurred in some of the animals treated intra-articularly with an injectable solution of hyaluronate sodium as it did in the saline treated control horses. No gross or histological lesions were observed in the soft tissues or the surface areas of the treated joint.

Storage

Store between 4°C and 25°C. Protect from sunlight.

PRESENTATION: NexHA® is supplied in cartons containing twelve 2 mL (20 mg) or twelve 4 mL (40 mg) single-use vials in addition to one 2 mL (20 mg) or one 4 mL (40 mg) single-use vial.

REFERENCE: 1 Swanstrom, O.G., Hyaluronate (hyaluronic acid) and its use, Proc. American Assoc. Equine Pract., 24th annual convention,1978. pp.345-348.

Registered Trademark of Vétoquinol USA, Inc.

Vétoquinol N.-A. Inc., 2000, ch. Georges, Lavaltrie, QC, Canada J5T 3S5

Date: June 14, 2013

100401A

NAC No.: 1234399.0

VETOQUINOL N.-A. INC.
Commercial Division

2000, CHEMIN GEORGES, LAVALTRIE, QC, J5T 3S5
Telephone:   450-586-2252
Order Desk:   800-363-1700
Fax:   450-586-4649
Website:   www.vetoquinol.ca
Email:   info@vetoquinol.ca
Every effort has been made to ensure the accuracy of the NexHA information published above. However, it remains the responsibility of the readers to familiarize themselves with the product information contained on the Canadian product label or package insert.

Copyright © 2016 North American Compendiums. Updated: 2016-08-21

Hide